Skip to Content

Banzel Approval History

  • FDA approved: Yes (First approved November 14th, 2008)
  • Brand name: Banzel
  • Generic name: rufinamide
  • Company: Eisai Medical Research Inc.
  • Treatment for: Lennox-Gastaut Syndrome

Banzel (rufinamide) is a triazole derivative antiepileptic drug for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

Development History and FDA Approval Process for Banzel

Feb 16, 2015Approval Eisai Receives Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients
Mar  4, 2011Approval FDA Approves Banzel (rufinamide) Oral Suspension, 40 mg/mL
Nov 17, 2008Approval FDA Approves Banzel (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder
Nov 18, 2005Eisai Resubmits NDA for the Anti-epilepsy Drug Rufinamide
Sep 13, 2005Eisai Submits New Drug Application to the FDA for Anti-epileptic Drug Rufinamide

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.